Disease · MONDO_0019313
lymphatic malformation
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. lymphatic malformation. Diseases, record MONDO_0019313. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0019313
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs7
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| SIROLIMUS | CHEMBL413 | Small molecule | Approval | PMDA | 4 | 3 | 3 | Drugs and targets |
| ALPELISIB | CHEMBL2396661 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BLEOMYCIN | CHEMBL6067492 | Phase 2 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets | |
| SILDENAFIL | CHEMBL192 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| DOXYCYCLINE | CHEMBL1200699 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SELENIUM | CHEMBL6068503 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OSI-027 | CHEMBL3120215 | Small molecule | Phase 1 | TTD | 1 | 0 | 0 | Drugs and targets |
Targets8
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 1 | FK506-binding protein 1A inhibitor | Approval | https://conductscience.org/library/genes/2280 | Drugs and targets |
| MMP1 | Interstitial collagenase | 1 | Matrix metalloproteinase-1 inhibitor | Phase 2 | https://conductscience.org/library/genes/4312 | Drugs and targets |
| MMP13 | Collagenase 3 | 1 | Matrix metalloproteinase 13 inhibitor | Phase 2 | https://conductscience.org/library/genes/4322 | Drugs and targets |
| MMP7 | Matrilysin | 1 | Matrix metalloproteinase 7 inhibitor | Phase 2 | https://conductscience.org/library/genes/4316 | Drugs and targets |
| MMP8 | Neutrophil collagenase | 1 | Matrix metalloproteinase 8 inhibitor | Phase 2 | https://conductscience.org/library/genes/4317 | Drugs and targets |
| MTOR | Serine/threonine-protein kinase mTOR | 1 | Serine/threonine-protein kinase mTOR inhibitor | Phase 1 | https://conductscience.org/library/genes/2475 | Drugs and targets |
| PDE5A | cGMP-specific 3',5'-cyclic phosphodiesterase | 1 | Phosphodiesterase 5A inhibitor | Phase 2 | https://conductscience.org/library/genes/8654 | Drugs and targets |
| PIK3CA | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | 1 | PI3-kinase p110-alpha subunit inhibitor | Phase 2/3 | https://conductscience.org/library/genes/5290 | Drugs and targets |
Trials11
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02335242 | Sildenafil for the Treatment of Lymphatic Malformations | Phase 2 | 22 | 2022-11-17 | Lymphatic Malformations, Lymphatic Diseases | SILDENAFIL | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01290484 | A Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations | Phase 1/2 | 7 | 2014-06-12 | Lymphangioma | SILDENAFIL | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT06943703 | Bleomycin as an Effective and Curative Adjunct Therapy for Lymphangioma | 809 | Lymphangioma, Lymphatic Malformations | BLEOMYCIN | Open Targets' reading of its record | ClinicalTrials.gov | ||
| NCT05948943 | Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. | Phase 2/3 | 232 | Lymphatic Malformations | ALPELISIB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT06437158 | Use of Bleomycin in the Sclerotherapy of Lymphatic Malformations for Pediatric Patients | Phase 2 | 200 | Lymphatic Malformation | BLEOMYCIN | Its record names the disease | ClinicalTrials.gov | |
| NCT07579962 | Treatment of Low-flow Vascular Malformations With Bleomycin Electrosclerotherapy (BEST) | Phase 2 | 140 | Vascular Malformations | BLEOMYCIN | Its record names the disease | ClinicalTrials.gov | |
| NCT07320001 | Injection Sclerotherapy With Bleomycin VS Doxycycline in Patients With Lymphatic Malformations | Phase 2 | 92 | Lymphatic Abnormality | BLEOMYCIN, DOXYCYCLINE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT03243019 | Efficacy of Rapamycin in the Treatment of Cervico-facial Lymphatic Malformations | Phase 2 | 28 | Lymphatic Malformation, Pediatric | SIROLIMUS | Its record names the disease | ClinicalTrials.gov | |
| NCT04861064 | Weekly Sirolimus Therapy | Phase 2 | 24 | Venous Malformation, Lymphatic Malformation | SIROLIMUS | Its record names the disease | ClinicalTrials.gov | |
| NCT04128722 | TOPical Sirolimus in linGUal Microcystic Lymphatic Malformation -TOPGUN | Phase 2 | 12 | Lingual Microcystic Lymphatic Malformations | SIROLIMUS | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 11
See all 11 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials15
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0019313
GET https://conductscience.org/api/diseases/v1/MONDO_0019313/drugs